trending Market Intelligence /marketintelligence/en/news-insights/trending/ymba7BIheJs3VQK7DpkZaA2 content esgSubNav
In This List

Novartis closing generics manufacturing division in Colorado, affecting 450 jobs

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Novartis closing generics manufacturing division in Colorado, affecting 450 jobs

Novartis AG is shuttering its Sandoz generic-drug manufacturing division in Broomfield, Colo., The Denver Post reported, citing company spokeswoman Sofina Mirza-Reid.

The closure, which will affect about 450 jobs, will be completed in phases and the company will transfer operations to a plant in Wilson, N.C. The closure and transfer are expected to be completed in the fourth quarter of 2019.

"Double-digit price erosion caused by customer consolidation and increased competition taking place within the U.S. generic drug market" caused the company to see above-average pricing pressure in the U.S., the news outlet reported, citing Mirza-Reid.